RAPT Therapeutics Announces Data, Including Objective Response Rates And Progression-Free Survival, From Its Phase 2 Trial Of FLX475 In Combination With A Checkpoint Inhibitor In Patients With Advanced NSCLC
Portfolio Pulse from Benzinga Newsdesk
RAPT Therapeutics has announced data from its Phase 2 trial of FLX475 in combination with a checkpoint inhibitor in patients with advanced non-small cell lung cancer (NSCLC). The trial showed a confirmed objective response rate (ORR) of 40% in PD-L1 positive patients with no prior checkpoint inhibitor therapy and a median progression-free survival (PFS) of 6.3 months. The company plans to advance the development of FLX475 based on these results.
November 03, 2023 | 4:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RAPT Therapeutics' Phase 2 trial data for FLX475 shows promising results, which could potentially boost investor confidence and positively impact the company's stock price in the short term.
The positive results from the Phase 2 trial of FLX475 in NSCLC patients indicate that the drug is effective and safe. This could potentially lead to increased investor confidence in RAPT Therapeutics, which could in turn lead to an increase in the company's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100